Manufacturer: Boehringer Ingelheim
Pradaxa's manufacturer, Boehringer Ingelheim, faces liability for losses and damages to its consumers because it did not warn patients of these risks. Furthermore, the drug maker has a history of negligence.
Boehringer Ingelheim produces a large number of medications to treat abdominal pain, bladder disorders, COPD (chronic obstructive pulmonary disease), respiratory disease, acid reflux, ulcers, cardiovascular disease, Parkinson's disease, HIV, and thromboembolic disease. The company’s more widely known products include Pradaxa, Zantac, Spiriva, Flomax, Dulcolax, and Metacam.
The FDA has issued multiple serious safety violations against this company.
In 2011, the FDA shut down a drug manufacturing plant that was a Boehringer Ingelheim subsidiary. Inspectors noted that the Ohio facility contained mold, rusty tools, and a barrel of urine. The company then spent $300 million to appropriately upgrade the plant.
Most recently, Boehringer’s blockbuster drug Pradaxa has been the center of controversy. Pradaxa is linked to thousands of injuries and hundreds of deaths from uncontrollable internal bleeding.
Within weeks of the FDA’s approval of Pradaxa, further research by MedWatch showed the agency had received more reports of side effects from Pradaxa than 98 percent of any of the other drugs on the market. Complaints included internal bleeding in the brain, intestines, and kidneys, as well as heart attacks.
On December 7, 2011, the FDA launched an investigation into Pradaxa following reports of 3,781 side effects and 542 deaths, the highest number of cases reported for any drug that year.